Federica Vacondio

Prof. Federica Vacondio


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2010 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
JCJason R Clapper
Jason R Clapper
GMGuillermo Moreno-Sanz
Guillermo Moreno-Sanz
Roberto russoRoberto russo
Roberto russo
AAAna Guijarro Anton
Ana Guijarro Anton
Federica VacondioFederica Vacondio
Federica Vacondio
DPDaniele Piomelli
Daniele Piomelli
The authors have developed a new inhibitor of the enzyme that degrades the endocannabinoid anandamide. This new drug does not cross the blood-brain barrier. It elevates peripheral anandamide only, which, acting on peripheral CB1 receptors, attenuates pain responses in rodents. Peripheral cannabinoid receptors exert a powerful inhibitory control over pain initiation, but the endocannabinoid signal that normally engages this intrinsic analgesic mechanism is unknown. To address this question, we developed a peripherally restricted inhibitor (URB937) of fatty acid amide hydrolase (FAAH), the enzyme responsible for the degradation of the endocannabinoid anandamide. URB937 suppressed FAAH activity and increased anandamide levels outside the rodent CNS. Despite its inability to access brain and spinal cord, URB937 attenuated behavioral responses indicative of persistent pain in rodent models of peripheral nerve injury and inflammation and prevented noxious stimulus–evoked neuronal activation in spinal cord regions implicated in nociceptive processing. CB1 cannabinoid receptor blockade prevented these effects. These results suggest that anandamide-mediated signaling at peripheral CB1 receptors controls the access of pain-related inputs to the CNS. Brain-impenetrant FAAH inhibitors, which strengthen this gating mechanism, might offer a new approach to pain therapy.

27 February 2014 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
ABAnna Berteotti
Anna Berteotti
Federica VacondioFederica Vacondio
Federica Vacondio
ALAlessio Lodola
Alessio Lodola
MBMichele Bassi
Michele Bassi
CSClaudia Silva
Claudia Silva
ACAndrea Cavalli
Andrea Cavalli

4 May 2010 in Drug Metabolism Reviews
Verified
Journal Article
Closed access
PDF file
Federica VacondioFederica Vacondio
Federica Vacondio
CSClaudia Silva
Claudia Silva
Marco MorMarco Mor
Marco Mor
BTBernard Testa
Bernard Testa
The aims of this review were 1) to compile a large number of reliable literature data on the metabolic hydrolysis of medicinal carbamates and 2) to extract from such data a qualitative relation between molecular structure and lability to metabolic hydrolysis. The compounds were classified according to the nature of their substituents (R3OCONR1R2), and a metabolic lability score was calculated for each class. A trend emerged, such that the metabolic lability of carbamates decreased (i.e., their metabolic stability increased), in the following series: Aryl-OCO-NHAlkyl >> Alkyl-OCO-NHAlkyl ∼ Alkyl-OCO-N(Alkyl)2 ≥ Alkyl-OCO-N(endocyclic) ≥ Aryl-OCO-N(Alkyl)2 ∼ Aryl-OCO-N(endocyclic) ≥ Alkyl-OCO-NHAryl ∼ Alkyl-OCO-NHAcyl >> Alkyl-OCO-NH2 > Cyclic carbamates. This trend should prove useful in the design of carbamates as drugs or prodrugs.

4 October 2006 in The Journal of Physiology
Verified
Journal Article
Closed access
RARoberta R. Alfieri
Roberta R. Alfieri
MBMara A. Bonelli
Mara A. Bonelli
ACAndrea Cavazzoni
Andrea Cavazzoni
MBMaurizio Brigotti
Maurizio Brigotti
CFClaudia Fumarola
Claudia Fumarola
PPPier Giorgio Petronini
Pier Giorgio Petronini

29 May 2008 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
Marco MorMarco Mor
Marco Mor
ALAlessio Lodola
Alessio Lodola
SRSilvia Rivara
Silvia Rivara
Federica VacondioFederica Vacondio
Federica Vacondio
ADAndrea Duranti
Andrea Duranti
DPDaniele Piomelli
Daniele Piomelli
Alkylcarbamic acid biphenyl-3-yl esters are a class of fatty acid amide hydrolase (FAAH) inhibitors that comprises cyclohexylcarbamic acid 3′-carbamoylbiphenyl-3-yl ester (URB597), a compound with analgesic, anxiolytic-like and antidepressant-like properties in rat and mouse models. Here, we extended the structure−activity relationships (SARs) for this class of compounds by replacing the cyclohexyl ring of the parent compound cyclohexylcarbamic acid biphenyl-3-yl ester (URB524) (FAAH IC50 = 63 nM) with a selected set of substituents of different size, shape, flexibility, and lipophilicity. Docking experiments and linear interaction energy (LIE) calculations indicated that the N-terminal group of O-arylcarbamates fits within the lipophilic region of the substrate-binding site, mimicking the arachidonoyl chain of anandamide. Significant potency improvements were observed for the β-naphthylmethyl derivative 4q (IC50 = 5.3 nM) and its 3′-carbamoylbiphenyl-3-yl ester 4z (URB880, IC50 = 0.63 nM), indicating that shape complementarity and hydrogen bonds are crucial to obtain highly potent inhibitors.

27 August 2009 in ChemMedChem
Verified
Journal Article
Open access
PDF file
JCJason R. Clapper
Jason R. Clapper
Federica VacondioFederica Vacondio
Federica Vacondio
AKAlvin R. King
Alvin R. King
ADAndrea Duranti
Andrea Duranti
ATAndrea Tontini
Andrea Tontini
DPDaniele Piomelli
Daniele Piomelli
The fatty acid ethanolamides are a class of signaling lipids that include agonists at cannabinoid and α type peroxisome proliferator‐activated receptors (PPARα). In the brain, these compounds are primarily hydrolyzed by the intracellular serine enzyme fatty acid amide hydrolase (FAAH). O‐aryl carbamate FAAH inhibitors such as URB597 are being evaluated clinically for the treatment of pain and anxiety, but interactions with carboxylesterases in liver might limit their usefulness. Here we explore two strategies aimed at overcoming this limitation. Lipophilic N‐terminal substitutions, which enhance FAAH recognition, yield potent inhibitors but render such compounds susceptible to attack by broad‐spectrum hydrolases and inactive in vivo. By contrast, polar electron‐donating O‐aryl substituents, which decrease carbamate reactivity, yield compounds, such as URB694, that are highly potent FAAH inhibitors in vivo and less reactive with off‐target carboxylesterases. The results suggest that an approach balancing inhibitor reactivity with target recognition produces FAAH inhibitors that display significantly improved drug‐likeness.